Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

@inproceedings{Stass2013InhalationOA,
  title={Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study},
  author={Heino Stass and Johannes Nagelschmitz and Stefan Willmann and Heinz Delesen and Abhishek Gupta and Sybille Baumann},
  booktitle={Clinical drug investigation},
  year={2013}
}
BACKGROUND Oral and intravenous formulations of ciprofloxacin have established efficacy and safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis' PulmoSphere™ technology has been developed to deliver high concentrations of ciprofloxacin to the lung with low systemic exposure using a portable and convenient passive dry powder inhaler (Novartis' T-326 inhaler). OBJECTIVES The primary objective was to investigate the safety and tolerability of… CONTINUE READING
17 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections (abstract no. R6156)

  • A Gupta, T Tarara, D Miller
  • American Association of Pharmaceutical Scientists…
  • 2011
2 Excerpts

Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with noncystic fibrosis

  • J Alder, R Wilson, T Welte
  • bronchiectasis. Amsterdam: European Respiratory…
  • 2011

on Antimicrobial Susceptibility Testing

  • EUCAST. European Committe
  • MIC distribution (online). http://www.eucast.org…
  • 2011
1 Excerpt

Pharmacokinetics of inhaled ciprofloxacin powder (abstract no. P103)

  • H Stass, S Baumann-Noss, H Delesen
  • Proceedings of 31st European Cystic Fibrosis…
  • 2008

Similar Papers

Loading similar papers…